ArticleCureus2025
Etoposide (VP-16)-Containing Oral Palliative Chemotherapies (OPCs) Are Well Tolerated by Elderly Patients With Aggressive Non-Hodgkin Lymphoma: A 10-Year Single-Institute Experience.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-Hodgkin lymphoma (NHL) is a malignant neoplasm with lymphoid-cell origin. Some patients are refractory to the treatments. Not all patients with relapsed/refractory NHL can benefit from intensive salvage therapy and novel drugs. Oral palliative chemotherapies (OPCs) are potentially good options for these patients through the alleviation of the lymphoma-related symptoms and the ability to stay at home for longer durations.
methodsEtoposide (VP-16)-containing OPCs are often used for aggressive NHL as palliative use at our institute. In order to elucidate the toxicity and efficacy of VP-16-OPCs, we retrospectively reviewed the patients at our institute with medical charts. We also reviewed the hospitalization-free period, indicating successful symptom palliation.
resultsFifty-six patients who received VP-16-OPCs at our institute between April 2012 and December 2023 were reviewed. Diseases include adult T-cell leukemia/lymphoma (ATLL), diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphoma (PTCL), and others. VP-16-OPCs include VENP, Sobuzoxane (MST)/VP-16, and VP-16+PSL (prednisolone). Infection was the most common non-hematological adverse event (34%). Nineteen out of 40 patients could complete more than two courses of VENP. Patients who responded to VP-16-OPCs tended to have longer event-free survival (EFS) (46 vs. 268 days, p < 0.01) and hospitalization-free periods (46 vs. 245 days, p = 0.11) compared to those who did not respond.
conclusionWe here reported the largest Japanese real-world dataset on VP-16-OPCs. The VP-16-OPCs were well tolerated by the patients, and some of them benefited from the treatment. These regimens can be considered when intensive and novel therapies are not indicated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.